

Exhibit 12

Staggering Cumulative Financial Harm: 2005-2017

Direct "Service Fee" and US Sales Fraud

(\$ million)

	Direct "Service Fee" Fraud (\$mil)¹	US Sales Fraud (\$mil)	Estimated Part D Market Share (%)
Enbrel (Amgen)	\$1,528	\$19,105	30%
Humira (AbbVie)	2,585	32,308	30%
Gleevec (Novartis)	542	7,436	60%
Tasigna (Novartis)	113	1,023	60%
Sprycel (Bristol-Myers)	199	2,514	60%
Lantus (Sanofi)	855	21,384	30%
Humulin (Eli Lilly)	165	4,124	30%
Lyrica (Pfizer)	395	9,885	30%
Viagra (Pfizer)	227	5,670	20%
Celebrex (Pfizer)	170	4,262	35%
Chantix (Pfizer)	61	1,525	15%
Premarin (Pfizer)	109	2,725	30%
Pristiq (Pfizer)	51	1,264	25%
Relpax (Pfizer)	17	421	15%
Total	\$7,017	\$113,647	

1 Using 8% PhRMA "specialty" drug average "service fee" contract rate.

Source: Corporate reports, PhRMA, Redbook/Truven, our estimates.

From the SDNY Amended Complaint, filed on August 3, 2018